1. Home
  2. MNSB vs XFOR Comparison

MNSB vs XFOR Comparison

Compare MNSB & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNSB
  • XFOR
  • Stock Information
  • Founded
  • MNSB 2003
  • XFOR 2014
  • Country
  • MNSB United States
  • XFOR United States
  • Employees
  • MNSB N/A
  • XFOR N/A
  • Industry
  • MNSB Major Banks
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MNSB Finance
  • XFOR Health Care
  • Exchange
  • MNSB Nasdaq
  • XFOR Nasdaq
  • Market Cap
  • MNSB 118.0M
  • XFOR 118.4M
  • IPO Year
  • MNSB N/A
  • XFOR N/A
  • Fundamental
  • Price
  • MNSB $19.05
  • XFOR $3.37
  • Analyst Decision
  • MNSB
  • XFOR Strong Buy
  • Analyst Count
  • MNSB 0
  • XFOR 3
  • Target Price
  • MNSB N/A
  • XFOR $72.33
  • AVG Volume (30 Days)
  • MNSB 25.4K
  • XFOR 145.5K
  • Earning Date
  • MNSB 04-21-2025
  • XFOR 05-01-2025
  • Dividend Yield
  • MNSB 2.10%
  • XFOR N/A
  • EPS Growth
  • MNSB N/A
  • XFOR N/A
  • EPS
  • MNSB N/A
  • XFOR 2.16
  • Revenue
  • MNSB $59,896,000.00
  • XFOR $31,364,000.00
  • Revenue This Year
  • MNSB $17.95
  • XFOR $355.69
  • Revenue Next Year
  • MNSB $2.52
  • XFOR $140.28
  • P/E Ratio
  • MNSB N/A
  • XFOR $1.55
  • Revenue Growth
  • MNSB N/A
  • XFOR N/A
  • 52 Week Low
  • MNSB $15.00
  • XFOR $3.05
  • 52 Week High
  • MNSB $20.88
  • XFOR $34.20
  • Technical
  • Relative Strength Index (RSI)
  • MNSB 62.71
  • XFOR 22.18
  • Support Level
  • MNSB $18.75
  • XFOR $3.05
  • Resistance Level
  • MNSB $20.09
  • XFOR $3.41
  • Average True Range (ATR)
  • MNSB 0.83
  • XFOR 0.62
  • MACD
  • MNSB 0.06
  • XFOR -0.02
  • Stochastic Oscillator
  • MNSB 69.23
  • XFOR 8.94

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Share on Social Networks: